You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Details for Patent: 9,186,332


✉ Email this page to a colleague

« Back to Dashboard


Title:Delayed release tablet with defined core geometry
Abstract: A tablet comprising a core containing an active agent, and a coating, the core being disposed within the coating such that the coating has a thickness about a longitudinal axis (X-Y) of about 4.85 to 4.95 mm. The position of the core within the coating dictating that the active agent is released rapidly after a lag time during which time no active agent is released.
Inventor(s): Vergnault; Guy (Kembs, FR), Grenier; Pascal (Kappelen, FR), Dragan; Christophe (Geispitzen, FR)
Assignee: Jagotec AG (Muttenz, CH)
Filing Date:Dec 13, 2012
Application Number:13/713,528
Claims:1. A method of administering a glucocorticosteroid active substance selected from prednisone, prednisolone, and methylprednisolone to a patient in need thereof comprising administering to the patient an oral dosage form comprising a defined core and a compression coating completely covering the core, wherein the core comprises the glucocorticosteroid active substance, wherein the compression coating comprises at least one material chosen from fatty acids or their esters or salts; long chain fatty alcohols; polyoxyethylene alkyl ethers; polyoxyethylene stearates; sugar esters; lauroyl macrogol-32 glyceryl; and stearoyl macrogol-32 glyceryl and further provided that the compression coating contains substantially no natural or synthetic gum; wherein the compression coating lacks ingredients that swell and gel to such an extent that the compression coating acts as a diffusion barrier to the release of the active substance, and wherein the compression coating is sufficiently porous to permit the ingress of aqueous media to the core at a rate to ensure release of the glucocorticosteroid active substance after a period of time between 2 to 6 hours wherein said period of time is followed by rupture of the compression coating.

2. The method according to claim 1, wherein the dosage form comprises 1 mg prednisone.

3. The method according to claim 1, wherein the dosage form comprises 5 mg prednisone.

4. The method according to claim 1, wherein the compression coating does not include a disintegrating agent.

5. The method according to claim 1, wherein the dosage form releases at least 80% of the glucocorticosteroid active substance after 4.5 hours.

6. The method according to claim 1, wherein the dosage form releases about 100% of the glucocorticosteroid active substance after 5 hours.

7. The method according to claim 2, wherein the coating does not include a disintegrating agent.

8. The method according to claim 2, wherein the dosage form releases at least 80% of the glucocorticosteroid active substance after 4.5 hours.

9. The method according to claim 2, wherein the dosage form releases about 100% of the glucocorticosteroid active substance after 5 hours.

10. The method according to claim 3, wherein the coating does not include a disintegrating agent.

11. The method according to claim 3, wherein the dosage form releases at least 80% of the glucocorticosteroid active substance after 4.5 hours.

12. The method according to claim 3, wherein the dosage form releases about 100% of the glucocorticosteroid active substance after 5 hours.

13. The method according to claim 1, wherein the compression coating is coated with an aesthetic coating.

14. The method according to claim 1, wherein the compression coating comprises 40 to 75% of a calcium phosphate salt, by weight of the coating.

15. The method according to claim 1, wherein the compression coating comprises about 5 to 85% glyceryl behenate, by weight of the coating.

16. The method according to claim 1, wherein the compression coating comprises from 30 to 50% glyceryl behenate, by weight of the coating.

17. The method according to claim 1, wherein said compression coating ruptures to form two hemispheres of coating material that may remain conjoined.

18. The method according to claim 1, wherein upon the ingress of aqueous media to the core, the core swells or effervesces.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.